QIAGEN Launches QIAstat-Dx Syndrome Tests in India

QIAGEN has launched two disease test panels for its QIAstat-Dx device in India, including the gastrointestinal panel two and meningitis/encephalitis panel, which have joined the SARS-CoV-2 flu group approved for emergency use for the first time in 2020.

This notice has received legal approval from the Central Drugs Standard Control Organization (CDSCO) to help healthcare providers in India accurately, quickly and easily check.

The QIAstat-Dx system is designed for laboratory use and uses refillable cartridges with all reagents and integrated sample handling capabilities. Detection and differentiation of multiple pathogens using real-time PCR. QIAstat-Dx also provides easy-to-view conversion threshold (Ct) values ​​and amplification curves, which can provide additional information unavailable using PCR or other methods.

"This group provides Indian healthcare professionals with a powerful tool for rapid and accurate diagnosis of infectious diseases, improving patient outcomes and reducing the burden on the healthcare system," said Manoj Jagathmohan, director and CEO of QIAGEN for India and South Asia.

The Meningitis/Encephalitis Panel simultaneously analyzes 15 viral, bacterial and fungal infections in patients with suspected central nervous system disease, and results are available within 80 minutes so that doctors can choose the proper treatment at the right time. According to the company, the test has high sensitivity and specificity, addressing the urgent need for rapid and reliable diagnosis of life-threatening diseases.

Development panel two can identify 22 clinically relevant bacteria, viruses and parasites that cause most gastrointestinal infections within an hour. According to the company, the equipment has significant advantages over traditional microbiology tests, which require samples to be cultured for 24 hours instead of 10 days.